New continuous glucose monitoring sensors (small sensors that penetrate the skin to measure glucose levels in real time) are ...

Time spent above, not below, the target glucose range was associated with mortality in a study of adults with type 2 diabetes ...

Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of ...

“It is important to understand the physiological time spent in specific ranges of CGM glucose for individuals without diabetes, which could serve as targets for individuals with diabetes or ...

Senseonics and Ascensia Diabetes Care have announced that the U.S. Food and Drug Administration has cleared the next-generation Eversense 365 CGM, the first one-year CGM system ...

Senseonics (NYSE:SENS) announced today that it received FDA clearance for its next-generation Eversense 365 CGM system.

Eversense 365 is a fully-implantable CGM with a 365-day sensor, making it the first 1-year CGM option for diabetes management ...

DUBLIN, Sept. 18, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today ...

Lexicon Pharmaceuticals (LXRX) announced that data from the SOTA-INS CGM Phase 3 randomized clinical trial showed that once-daily ...

The U.S. FDA cleared Senseonic Holdings Inc.’s Eversense 365, the first continuous glucose monitor to last a full year with a single sensor rather than the 10 days to two weeks typical for wearable ...

Senseonics Holdings, Inc. (NYSE: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with ...